2026-08-29T14:05:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/189832024-11-29T08:15:42Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Fontán-Vela, Mario author Kissling, Esther author Nicolay, Nathalie author Braeye, Toon author Van Evercooren, Izaak author Holm Hansen, Christian author Emborg, Hanne-Dorthe author Fabiani, Massimo author Mateo-Urdiales, Alberto author AlKerwi, Ala'a author Schmitz, Susanne author Castilla, Jesús author Martínez-Baz, Iván author de Gier, Brechje author Hahné, Susan author Meijerink, Hinta author Starrfelt, Jostein author Nunes, Baltazar author Caetano, Constantino author Derrough, Tarik author Nardone, Anthony author Monge Corella, Susana author VEBIS-Lot4 working group author 2024-01 To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds. Euro Surveill. 2024 Jan;29(1):2300670. 10.2807/1560-7917.ES.2024.29.1.2300670 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 38179626 http://hdl.handle.net/20.500.12105/18983 COVID-19 SARS-CoV-2 Cohort design Electronic health records Hospitalisation Multi-country study Vaccine effectiveness Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023